Objective.-To determine if serum vascular endothelial growth factor (VEGF) and ultrasonic monitoring of vascular dynamics with dynamic vascular analysis at sea level and high altitude correlate with acute mountain sickness symptoms.
Introduction
Acute mountain sickness (AMS) represents an increasing clinical problem at higher altitude 1, 2 ; if unrecognized and untreated, it may lead to death in just a few hours. Although well documented, no conclusive physiological evidence exists to link increased cerebral blood flow (CBF) secondary to hypobaric hypoxia to the development of AMS or high-altitude cerebral edema. Serum vascular endothelial growth factor (VEGF) levels have been measured in subjects exposed to altitude; however, changes do not correlate with development of altitude illness. [3] [4] [5] Hypoxemia constricts pulmonary vessels, 6 whereas in the cerebrum it causes hyperemia. 7 However, both vascular territories develop endothelial dysfunction with edema at higher altitude. Human transcranial Doppler (TCD) studies at high altitude revealed increased middle cerebral artery (MCA) mean flow velocities (MFVs) secondary to hypoxemic drive, 8 yet changes in MFV in the MCA do not predict subjects who develop AMS. 9 Transcranial Doppler studies of the MCA at altitude have demonstrated diminished index of pulsatility (PI) or index of resistance [10] [11] [12] but with unclear clinical implications.
We investigated the impact of increasing altitude as a function of graded hypoxemic stress by correlating CBF dynamics informed by dynamic vascular analysis (DVA) 13 of TCD-derived velocimetry data, serum VEGF levels, and 4 sickness symptom scales. We utilized DVA to assess cerebrovascular physiology, allowing for sensitive monitoring of changes in cerebrovascular physiology associated with changes in altitude.
Methods
The institutional review board at the Uniformed Services University of the Health Sciences, Bethesda, MD, approved this prospective, longitudinal, single-arm, singleblind pilot trial. Nine healthy, athletic male subjects who were medical faculty and PhD candidates from the Uniformed Services University of the Health Sciences who signed informed consent forms were taken from sea level to the summit of Pikes Peak, CO, at 4300 m (altitude). The ascent up the mountain was staged for 5 days with daily stops and testing at 1585 m, 2500 m, and 3415 m and a final ascent to 4300 m (summit). All volunteers were given the following questionnaires at each altitude to measure severity of altitude illness: Lake Louise score, Spielberger-1 score, Subjective Exercise Experiences Scale positive score, and Symptom Checklist-90 surveys. [14] [15] [16] [17] Transcranial Doppler data were acquired by a single technologist (nonsubject) from recumbent subjects at each altitude by well-documented handheld techniques and depth of measurement 18 with a Pioneer Companion system (Nicolet Vascular, Golden, CO) having a 2-MHz probe. Velocimetry measurements were taken from both MCAs M1 (50-60 mm), both anterior cerebral arteries A1 (60-70mm), both posterior cerebral arteries, both P1 (60-70 mm) and P2 (60-70 mm), both vertebral arteries (60-65 mm), and the basilar artery (80-100 mm). New Health Sciences Inc (Rockville, MD) performed the DVA analysis according to previously reported methods. 13 This analysis now includes the dynamic flow index (DFI ϭ MFV/PI), dynamic pressure index (DPI ϭ natural log of systolic acceleration)/ PI), and dynamic compliance index (DCI ϭ natural log of systolic acceleration/MFV). The DFI relates MFV to resistance (PI) and reflects small vessel effects on flow through conductance vessels. The DPI relates acceleration or force of flow to the downstream resistance and relates the effects of small vessel volume on the force of flow or the pressure gradient on which the blood flows. The DCI relates acceleration or force of flow to MFV and reflects the elasticity and kinetic efficiency of pulse wave propagation in the vessel segment insonated. Blood samples were taken at each altitude and immediately centrifuged at 3400g for 20 minutes to separate the serum, which was subsequently flash frozen in the field and sent for proteomic VEGF characterization by the Advanced Concepts Laboratory of the National Cancer Institute, National Institutes of Health, Bethesda, MD (Dr Steven Libuttis).
All 9 subjects completed the study up to 3415 m. Only 8 subjects fully completed the study at summit altitude. One subject experienced acute altitude illness 2 hours after ascent, with ataxia, bilateral papilledema, confusion, and disorientation to person, place, and time. He recovered spontaneously without sequelae after emergent descent to 3650 m. Transcranial Doppler velocimetry data were collected from this subject at the summit before descent, but no blood sample or symptom scores were obtained. Symptom scores were all assumed to be severe in this subject because he was incapable of answering the questionnaires at altitude. To include him in the analysis, he was assigned a total Lake Louise score of 30, a Symptom Checklist-90 score of 90, and a Spielberger-1 score of 60 at 4300 m. Nonparametric statistical methods based on ranks were used for all analysis involving symptom scales, so the absolute numerical score was not as important because the scores were higher than those recorded by the other subjects.
Mean flow velocity, systolic upstroke acceleration (SA), PI, VEGF, and symptom scores were compared by using the Wilcoxon signed rank test. A significant difference was considered at P Ͻ .05. Symptom scores at altitude were compared with MFV, natural log of systolic acceleration, PI, VEGF, DFI, DPI, and DCI scores at all altitudes by using Spearman rank correlation (r). Spearman rank correlations lie between ϩ1 and Ϫ1, and a correlation of 0 indicates no relationship. A positive correlation indicates that an increase in that measure corresponds to an increase in symptoms, whereas a negative correlation indicates that a decrease in that measurement corresponds to a decrease in symptoms. The analysis focused on the relationship to symptom scales at final altitude because subjects experienced varied symptoms at lower altitudes.
Symptom scores were compared with changes in the other variables as follows:
• For each subject, the slope of the linear regression for the PI at each altitude was calculated. A positive slope indicated that PI increased with increasing altitude; conversely, a negative slope indicated that PI decreased with increasing altitude.
• Spearman rank correlation was used to compare the slope of the regression with a symptom score for every subject. A negative correlation indicated that a subject whose PI increased with increased altitude (positive slope) had fewer symptoms.
• This analysis was repeated for every variable. Figure 2 . Effect of summit altitude (4300 m) on Lake Louise symptom scores. The difference in symptom scales between the symptomatic group (n ϭ 3) and the asymptomatic group (n ϭ 6) became significant at peak altitude. Means and ranges for Lake Louise scores are shown. All symptom scales showed similar differences.
Figure 3. Effect of altitude on index of pulsatility (PI).
Changes in PI significantly differed between the 2 symptom groups with altitude (*P Ͻ .05; paired-samples t test).
• For each TCD measurement, average change from sea level to 4300 m was calculated for symptomatic (Sx) and asymptomatic (Asx) subjects, and the 2 groups were compared by using the paired-samples t test.
Results
We observed changes in TCD values, confirming increased MFV with increasing altitude in every subject ( Figure 1) , with a holocephalic, median level increasing from 46.64 cm·s Ϫ1 at sea level to a median of 55.32 cm·s Ϫ1 at altitude (P ϭ .008). There was no significant cohort change in holocephalic PI with increasing altitude: the PI increased in 5 subjects and decreased in 4 subjects.
There was no cohort change in mean VEGF level with altitude: 5 subjects experienced increased VEGF, 2 subjects had no change, and 2 subjects had a peak value at 3415 m with a decrease in VEGF at summit altitude.
Symptoms scales increased for most subjects with increasing altitude. The median number of reported symptoms increased from 1 at sea level to 15 at altitude (P ϭ .008) on the Symptom Checklist-90 scale, from 23 at sea level to 25 at altitude (P ϭ .063) on the Spielberger-1 scale, and from 1 at sea level to 9 at altitude (P ϭ .008) on the Lake Louise questionnaire (Figure 2 ).
Subjects with a high PI at every altitude above sea level reported fewer symptoms at final altitude (Ϫ0.04 Ͻ Ͻ Ϫ0.79). Subjects whose PI increased with increasing altitude had far fewer symptoms than those subjects whose PI decreased with increasing altitude ( Figure  3) . Because of this relationship, the group was subcategorized into an Sx group with 3 subjects and an Asx group with 6 subjects ( Table 1) .
Comparisons of TCD, DVA, and VEGF levels between the 2 groups at sea level and altitude, as well as analysis comparing changes between sea level and altitude within the Sx and the Asx groups, were performed ( Table 2) . At altitude, we noted significant group differences (P Ͻ .05) between the groups regarding PI ( Figure  3 ) and DFI (Figure 4) . Trending, but not a significant difference, was noted in the DPI and the serum VEGF level ( Figure 5 ). We noted a dramatic drop in serum VEGF level at high altitude in the Sx group. This drop indicates complex kinetics of serum VEGF in hypoxic environments.
Discussion
Noninvasive monitoring of cerebrovascular dynamics with changing altitude revealed that increased hypox- emia in the Sx group was associated with increasing DFI and diminished pulsatility, suggesting reduced vascular resistance from expanding capacitance vessel volume. The present study confirmed previous altitude studies demonstrating that MFV increased in the MCA, 7, 11, 19, 20 increasing more in AMS. 11, 19, 20 Previous studies also revealed that cerebral MFV increased with moderate exercise at altitude but decreased with intense exercise in subjects developing AMS, 20, 21 indicating diminished metabolic reserve or hypoxemic tolerance. In animals, hypoxic drive was demonstrated to have nonlinear relationships to increased CBF 22 regardless of hypocarbia from hyperventilation. 23 Previous altitude studies demonstrated decreased carbon dioxide response or capacitance vessel reserve 20, 24 in all subjects, including native Sherpas, regardless of AMS symptoms. 24 A clear relationship exists at altitude between MFV and capacitance vessel reserve.
Capacitance vessel dilation from hypoxemic stress will improve minute oxygen delivery 24 by increasing overall CBF. Capacitance vessel reserve is mediated by myogenic contraction not affected by hypoxia but cannot override the potent effects of hypoxic vasodilation itself. 25 Vasodilation is affected by metabolic alterations caused by hypoxemia, including increased cerebrospinal fluid pH, 26 increased hematocrit, 27 increased hemoglo- The DFI (mean flow velocity/index of pulsatility) significantly increased in the symptomatic group compared with the asymptomatic group (*P Ͻ .05; paired-samples t test). Figure 5 . Effect of altitude on serum vascular endothelial growth factor (VEGF). Serum VEGF levels dropped initially at 1585 m in the symptomatic (Sx) group, then the levels for both the Sx group and the asymptomatic (Asx) group increased until 3415 m, where the Sx group fell precipitously and the Asx group had a slight decline. These findings were not significant.
bin, and decreased nitric oxide, 28 partially explaining acclimatization and stabilization of CBF at altitude. One possible mechanism for the development of AMS is impairment of endothelial gap junction function secondary to hypoxemia 3,29-32 characterized by increased permeability to macromolecules and increasing interstitial free water, which may result in high-altitude cerebral edema 33 and high-altitude pulmonary edema as well as expansion of capacitance vessel volume.
High-altitude cerebral edema may be secondary to increased endothelial permeability of cerebral capacitance or small vessels. 12, 33 Hypoxemic stress increases production of VEGF 3, 34, 35 and VEGF receptors, 5 which increase vascular permeability. Levels of VEGF correlate with altitude symptoms compared with sea level controls; however, at altitude, VEGF did not correlate with these same symptoms. 5 This suggests variable responses to increasing VEGF, as suggested by our cohort. Our increase in VEGF did not reach significance but suggested an oxidative stress. Vascular endothelial growth factor increases vessel permeability. 33 Increased dysfunction of the endothelial tight junctions and adherens junctions with increasing oxidative stress is known. A recent study involving rats showed direct evidence of increased permeability to larger molecular weight compounds with hypoxia. 36 The increased fenestrations in the endothelial barrier leak serum proteins into interstitial spaces, pulling free water. This may explain the drop in serum VEGF levels observed in our Sx subjects. If these ''vascular holes'' open, then a drop in intravascular pressure would occur in capacitance vessels, thereby diminishing capillary perfusion pressure and conductance vessel resistance as observed in this study. As resistance drops, flow increases to maintain adequate minute perfusion of the capillaries. Interestingly, if enough of these gaps were open, a relative drop in intraluminal pressure of a ''closed'' vascular system would occur because this new state would represent an ''open'' system, causing increased flow with less work provided by the conductance system to maintain the pressure gradient. This correlates with our findings that the PI in conductance vessels diminished, as did the vessel tone (decreased DCI) secondary to increased vessel volume (increased DFI) in the Sx group. The appropriate compensatory mechanism would increase capacitance vessel myogenic tone to increase intravascular pressure of this now-open system and increase forward perfusion pressure, thereby increasing the pressure gradient across the capillary beds. This compensatory change was evident in the Asx group but not in the Sx group.
Our study differs from other TCD-derived velocimetry studies at altitude in that holocephalic (including the posterior circulation) changes were monitored in contrast to other studies of an isolated cerebral vessel segment. This approach demonstrated that changes in CBF at altitude are holocephalic and that changes in the posterior circulation are present. Cerebral blood flow increases as a result of a medullary response to hypoxia 37 mediated by a relay through the thalamus to dilate cortical vessels. This underscores the importance of monitoring posterior circulation flow when studying the pathophysiology of AMS.
In this cohort, changes in the conductance vessel SA and DCI, as markers of perfusion pressure and vessel tone, respectively, correlated with symptom scores and serum VEGF levels. Less symptomatic subjects had higher VEGF scores, with the ability to maintain cere-brovascular compliance (ie, higher DCI and perfusion pressure, SA). Symptomatic subjects had increased vascular tone with lower VEGF levels, suggesting increased vascular tone reflected as decreased DCI or PI. The most striking finding in our study was the reverse relationship of symptom scores to the PI. As PI diminished (lower vascular resistance secondary to expansion of capacitance vessel volume), symptoms increased.
This study was underpowered to show significant group changes, a possible type 2 error. Although serum VEGF levels were trending, this study suggests that studies with more subjects would show significant differences in VEGF levels between the symptom groups. We run the risk of a type 1 error given the number of subjects in this study. Pooling of all vessel data minimized this risk.
In summary, this DVA-enabled study indicates that acute mountain sickness is associated with altered cerebrovascular kinetics and volume expansion as a function of dysfunctional capacitance vessels. At altitude, increased permeability of the vascular endothelium from opening of endothelial junctions in capacitance vessels most likely precedes increasing symptoms and eventually high-altitude cerebral edema and high-altitude pulmonary edema. Dynamic vascular analysis proved to be a sensitive tool for measuring and elucidating the vascular physiology behind changes in CBF dynamics associated with symptomatic altitude illness. Potential therapies directed at maintaining the integrity of endothelial junctions and capacitance vessel tone to prevent acute altitude sickness or other hypoxemic states could be noninvasively monitored with DVA.
